Evanston, United States
Rhaeos is a VC backed, clinical stage medical device company founded in 2018. The company has gained recognition for its innovation, with its wearable sensor technology, FlowSense, earning FDA breakthrough designation. The noninvasive wireless skin patch monitors fluid flow subdermally, initially targeting hydrocephalus. Rhaeos has secured substantial funding, with NIH and NSF support amounting to over $7.5M. The company's last investment of $1.50M came from the National Institutes of Health, endorsing their potential in the medical device industry.
Rhaeos has demonstrated its expertise in the field, publishing clinical data in renowned journals and earning recognition as the top winner in the MedTech Innovator competition. The company's progress is reflected in its financials, having raised over $19M in dilutive and non-dilutive financing. With an anticipated market entry in 2024, Rhaeos's future looks promising as it expands its product line to address other chronic conditions. The innovative and disruptive nature of FlowSense positions Rhaeos as a key player in the biotechnology and healthcare sectors, with potential for significant positive impact on patient care and outcomes.
